Moreover, urotensin 2 inhibits insulin release, has inotropic and hypertrophic effects on heart muscle, and is a proposed biomarker of cardio-metabolic disorders including hypertension, atherosclerosis, heart failure, pulmonary hypertension, diabetes, renal failure and metabolic syndrome [45]. Here, INS is linked to metabolic syndrome.